5月31日 演題レポート
PHS=Poster Highlights Session,
GPS=General Poster Session,
CSS=Clinical Science Symposia
Abstract #3514 / #3515
Abstract #3514
Phase I Study of the Selective BRAFV600 Inhibitor Encorafenib (LGX818) Combined with Cetuximab and with or without the α-specific PI3K Inhibitor BYL719 in Patients with Advanced BRAF-mutant Colorectal Cancer
Robin Van Geel, et al.
Abstract #3515
Evidence of Efficacy and Tolerability in an Open-label Phase I/II Study of MEK Inhibitor Trametinib (T), BRAF Inhibitor Dabrafenib (D) and Anti-EGFR Antibody Panitumumab (P) in Combination in Patients (pts) with BRAF V600E Mutated Colorectal Cancer
Johanna C. Bendell, et al.
Abstract #3519
Subgroup Analyses in RAS Mutant, BRAF Mutant and All-wt mCRC Patients Treated with FOLFOXIRI plus Bevacizumab (Bev) or FOLFIRI plus Bev in the TRIBE Study
Fotios Loupakis, et al.
Abstract #3521
Amphiregulin (AREG) SNP rs1615111 to Predict Cetuximab Efficacy Independent of AREG mRNA Levels: Data from FIRE-3 (AIO KRK-0306)
Sebastian Stintzing, et al.
Abstract #3524
Phase II Study of Single-agent Cetuximab in KRAS G13D Mutant Metastatic Colorectal Cancer (mCRC)
Marta Schirripa, et al.
Abstract #3527
Surgical Impact of Surgical Resection of Primary Tumors (SRPT) in Metastatic Colorectal Cancer (mCRC): A Population Based Cohort Study
Shahid Ahmed, et al.
Abstract #3528
Surgical Outcome for Pulmonary Metastasis of Colorectal Cancer in the Modern Chemotherapy Era: Results of a Retrospective Japanese Multicenter Study
Tomoyuki Hishida, et al.
Abstract #3534
A Randomized Phase III Trial of mFOLFOX6 plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-line Treatment for Metastatic Colorectal Cancer: WJOG4407G
Kentaro Yamazaki, et al.
Abstract #3543
An Internally and Externally Validated Nomogram to Predict Severe Neutropenia in Japanese Patients (pts) with Advanced Colorectal Cancer (aCRC) Treated with Irinotecan (IRI)-based Regimens
Wataru Ichikawa, et al.
Abstract #3550
Survival Outcomes in Patients with KRAS /NRAS (RAS) Wild-type Metastatic Colorectal Cancer and Non-liver-limited Disease: Data from the PRIME Study
Jean-Yves Douillard, et al.
Abstract #3584
A Randomized Controlled Trial Evaluating Efficacy of Adjuvant Oral Uracil-tegafur (UFT) with Leucovorin (LV) after Resection of Colorectal Cancer Liver Metastases: The UFT/LV Study
Akira Kobayashi, et al.
Abstract #3586
Updated Results of the SOFT Study: A Randomized Phase III Trial of S-1/Oxaliplatin (SOX) plus Bevacizumab versus 5-FU/l-LV/Oxaliplatin (mFOLFOX6) plus Bevacizumab in Patients with Metastatic Colorectal Cancer (mCRC)
Masato Nakamura, et al.
Abstract #3587
KRAS 野生型の切除不能進行・再発大腸癌に対する3rd-lineとしてのPanitumumabの皮膚障害に関する無作為化比較試験：HGCSG1001試験 (J-STEPP試験)－抗腫瘍効果の追加解析
Randomized Controlled Trial on the Skin Toxicity of Panitumumab in Third-line Treatment of KRAS Wild-type Metastatic Colorectal Cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol with Panitumumab: J-STEPP)-Additional Analysis of Anti-tumor Efficacy
Yoshimitsu Kobayashi, et al.
Abstract #3600 / #3597
Abstract #3600
Gender and Tumor Location as Predictors of Efficacy in 1st-line Treatment with FOLFIRI plus Cetuximab or Bevacizumab: Results from the AIO KRK-0306 (FIRE-3) Trial
Volker Heinemann, et al.
Abstract #3597
Molecular Profiling of EGFR Pathway According to Location of Colorectal Cancer (CRC): Analysis of 1,001 Patients in Single Institute
Eiji Shinozaki, et al.
Abstract #3603
Final Results from NSABP Protocol R-04 - Neoadjuvant Chemoradiation Comparing Continuous Infusion 5-FU with Capecitabine with or without Oxaliplatin in Patients with Stage II & III Rectal Cancer
Carmen Joseph Allegra, et al.
Abstract #3608
S-1 plus Oxaliplatin versus Capecitabine plus Oxaliplatin for the First-line Treatment of Patients with Metastatic Colorectal Cancer: Updated Results from a Phase 3 Trail
Young Suk Park, et al.
Abstract #3629
Extended RAS Analysis and Subsequent Anti-EGFR and Anti-VEGF Treatment in PEAK: A 1st-line Phase 2 Study of FOLFOX6 + Panitumumab or Bevacizumab in Metastatic Colorectal Cancer
Fernando Rivera, et al.
Abstract #3646
A Phase II Study of 5-FU/I-LV/Oxaliplatin (mFOLFOX6) in Patients with Metastatic or Unresectable Small Bowel Adenocarcinoma
Norisuke Nakayama, et al.